| Total | SSEA-4 positive | SSEA-4 negative | p-value | |
| Subjects | 38 | 14 | 24 | |
| Sex | ||||
| Female | 7 (18) | 2 (14) | 5 (21) | 0.615 |
| Male | 31 (82) | 12 (86) | 19 (79) | |
| Age yrs | 66.0±8.2 | 61.9±7.6 | 0.143 | |
| ECOG# | ||||
| 0 | 28 (74) | 11 (79) | 17 (71) | 0.601 |
| ≥1 | 10 (26) | 3 (21) | 7 (29) | |
| UICC stage | ||||
| IA | 6 (16) | 2 (14) | 4 (17) | 0.899 |
| IB | 13 (34) | 4 (29) | 9 (37) | |
| IIA | 8 (21) | 3 (21) | 5 (21) | |
| IIB | 11 (29) | 5 (36) | 6 (25) | |
| pT | ||||
| T1 | 10 (26) | 4 (29) | 6 (25) | 0.809 |
| T2 | 28 (74) | 10 (71) | 18 (75) | |
| pN | ||||
| N0 | 21 (55) | 7 (50%) | 14 (58) | 0.618 |
| N1 | 17 (45) | 7 (50%) | 10 (42) | |
| Type of resection | ||||
| Pneumonectomy | 6 (16) | 4 (29) | 2 (8) | 0.247 |
| Bilobectomy | 4 (10) | 1 (7) | 3 (13) | |
| Lobectomy | 28 (74) | 9 (64) | 19 (79) | |
| Relapse % | ||||
| Total | 16 (42) | 11 (79) | 5 (21) | 0.000 |
| Local | 1 (3) | 0 (0) | 1 (4) | NA |
| Distant | 15 (39) | 11 (79) | 4 (17) | NA |
| Mortality % | ||||
| Total | 14 (37) | 9 (64) | 5 (21) | 0.011 |
| Yes | 13 (34) | 9 (64) | 4 (17) | NA |
| No | 1 (3) | 0 (0) | 1 (4) | NA |
| Disease-free survival months | NR | 11.1 (4.3–45.1) | NR | NA |
| Overall survival months | NR | 45.0 (14.5–NR) | NR | NA |
| Survival rate % | ||||
| 1-yr | 91.7 (82.7–100) | 85.1 (66.0–100) | 95.7 (87.3–100) | NA |
| 2-yr | 83.0 (70.6–95.5) | 69.6 (44.7–94.6) | 90.9 (78.7–100) | |
| 5-yr | 61.9 (44.4–79.4) | 35.4 (8.1–62.7) | 80.1 (64.4–97.8) | |
| Follow-up months | 72.9 (42.7–91.5) | 91.4 (42.7–96.3) | 70.2 (37.5–84.2) | NA |
Data are presented as n, n (%), mean±sem or median (95% CI), unless otherwise stated. SSEA-4: stage-specific embryonic antigen-4; ECOG: Eastern Cooperative Oncology Group; UICC: Union Internationale Contre le Cancer; NR: not reached; NA: not applicable. p-values in bold are statistically significant. #: ECOG 0 is a patient without physical restriction and ECOG≥1 is a patient with increasing physical restriction. Bold indicates statistical significance.